These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33223554)

  • 21. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty.
    Andrews SM; Pollard AJ
    Lancet Infect Dis; 2014 May; 14(5):426-34. PubMed ID: 24679664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.
    De Serres G; Billard MN; Gariépy MC; Rouleau I; Toth E; Landry M; Boulianne N; Gagné H; Gilca V; Deceuninck G; Ouakki M; Skowronski DM
    Vaccine; 2018 Dec; 36(52):8039-8046. PubMed ID: 30467063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use and misuse of media headlines: lessons from the MeNZB immunisation campaign.
    Turner NM; York DG; Petousis-Harris HA
    N Z Med J; 2009 Mar; 122(1291):22-7. PubMed ID: 19322252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N
    Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study.
    Chiu NC; Huang LM; Willemsen A; Bhusal C; Arora AK; Reynoso Mojares Z; Toneatto D
    Hum Vaccin Immunother; 2018 May; 14(5):1075-1083. PubMed ID: 29337653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination.
    Thabuis A; Tararbit K; Taha MK; Dejour-Salamanca D; Ronin V; Parent du Chatelet I; Spaccaferri G
    Euro Surveill; 2018 Jul; 23(28):. PubMed ID: 30017022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease.
    O'Hallahan J; Lennon D; Oster P; Lane R; Reid S; Mulholland K; Stewart J; Penney L; Percival T; Martin D
    Vaccine; 2005 Mar; 23(17-18):2197-201. PubMed ID: 15755594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mum's the word: factors that influenced young adults' participation in the New Zealand Meningococcal B immunisation programme.
    Bland M; Clear GM; Grogan A; Hoare K; Waldock J
    N Z Med J; 2009 Dec; 122(1307):30-8. PubMed ID: 20148042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The strategy to control New Zealand's epidemic of group B meningococcal disease.
    O'Hallahan J; Lennon D; Oster P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
    Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M
    Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
    Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
    Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak.
    Caron F; du Châtelet IP; Leroy JP; Ruckly C; Blanchard M; Bohic N; Massy N; Morer I; Floret D; Delbos V; Hong E; Révillion M; Berthelot G; Lemée L; Deghmane AE; Bénichou J; Lévy-Bruhl D; Taha MK
    Lancet Infect Dis; 2011 Jun; 11(6):455-63. PubMed ID: 21489881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease.
    Watson PS; Turner DP
    Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines.
    Oviedo-Orta E; Ahmed S; Rappuoli R; Black S
    Vaccine; 2015 Jul; 33(31):3628-35. PubMed ID: 26093201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of meningococcal group B OMV vaccines, beyond their brief.
    Petousis-Harris H
    Hum Vaccin Immunother; 2018 May; 14(5):1058-1063. PubMed ID: 29048985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.
    Djingarey MH; Barry R; Bonkoungou M; Tiendrebeogo S; Sebgo R; Kandolo D; Lingani C; Preziosi MP; Zuber PL; Perea W; Hugonnet S; Dellepiane de Rey Tolve N; Tevi-Benissan C; Clark TA; Mayer LW; Novak R; Messonier NE; Berlier M; Toboe D; Nshimirimana D; Mihigo R; Aguado T; Diomandé F; Kristiansen PA; Caugant DA; Laforce FM
    Vaccine; 2012 May; 30 Suppl 2():B40-5. PubMed ID: 22607898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Group B meningococcal vaccine science and policy.
    Drysdale SB; Pollard AJ
    J Infect; 2015 Jun; 71 Suppl 1():S15-20. PubMed ID: 25917798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging experience with meningococcal serogroup B protein vaccines.
    Toneatto D; Pizza M; Masignani V; Rappuoli R
    Expert Rev Vaccines; 2017 May; 16(5):433-451. PubMed ID: 28375029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.